vs
Apellis Pharmaceuticals, Inc.（APLS）与西蒙地产集团（ELS）财务数据对比。点击上方公司名可切换其他公司
西蒙地产集团的季度营收约是Apellis Pharmaceuticals, Inc.的2.0倍（$397.6M vs $199.9M），西蒙地产集团同比增速更快（2.7% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.3%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
西蒙地产集团是美国头部房地产投资信托企业，投资范围涵盖购物中心、奥特莱斯及社区生活中心等商业地产业态，是美国规模最大的购物中心持有方，总部位于印第安纳州印第安纳波利斯，截至2024年12月末共持有232处物业权益。
APLS vs ELS — 直观对比
营收规模更大
ELS
是对方的2.0倍
$199.9M
营收增速更快
ELS
高出8.6%
-5.9%
两年增速更快
APLS
近两年复合增速
2.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $397.6M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 2.7% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.56 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSELS
| Q1 26 | — | $397.6M | ||
| Q4 25 | $199.9M | $373.9M | ||
| Q3 25 | $458.6M | $393.3M | ||
| Q2 25 | $178.5M | $376.9M | ||
| Q1 25 | $166.8M | $387.3M | ||
| Q4 24 | $212.5M | $372.3M | ||
| Q3 24 | $196.8M | $387.3M | ||
| Q2 24 | $199.7M | $380.0M |
净利润APLSELS
| Q1 26 | — | — | ||
| Q4 25 | $-59.0M | $103.8M | ||
| Q3 25 | $215.7M | $100.4M | ||
| Q2 25 | $-42.2M | $83.5M | ||
| Q1 25 | $-92.2M | $114.4M | ||
| Q4 24 | $-36.4M | $100.6M | ||
| Q3 24 | $-57.4M | $86.9M | ||
| Q2 24 | $-37.7M | $82.1M |
营业利润率APLSELS
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 26.5% | ||
| Q3 25 | 48.7% | 25.1% | ||
| Q2 25 | -18.6% | 22.3% | ||
| Q1 25 | -50.0% | 28.3% | ||
| Q4 24 | -12.3% | 27.2% | ||
| Q3 24 | -24.0% | 21.4% | ||
| Q2 24 | -14.7% | 21.5% |
净利率APLSELS
| Q1 26 | — | — | ||
| Q4 25 | -29.5% | 27.8% | ||
| Q3 25 | 47.0% | 25.5% | ||
| Q2 25 | -23.6% | 22.2% | ||
| Q1 25 | -55.3% | 29.5% | ||
| Q4 24 | -17.1% | 27.0% | ||
| Q3 24 | -29.2% | 22.4% | ||
| Q2 24 | -18.9% | 21.6% |
每股收益（稀释后）APLSELS
| Q1 26 | — | $0.56 | ||
| Q4 25 | $-0.40 | $0.52 | ||
| Q3 25 | $1.67 | $0.50 | ||
| Q2 25 | $-0.33 | $0.42 | ||
| Q1 25 | $-0.74 | $0.57 | ||
| Q4 24 | $-0.30 | $0.51 | ||
| Q3 24 | $-0.46 | $0.44 | ||
| Q2 24 | $-0.30 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.8B |
| 总资产 | $1.1B | $5.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSELS
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
总债务APLSELS
| Q1 26 | — | — | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $3.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益APLSELS
| Q1 26 | — | $1.8B | ||
| Q4 25 | $370.1M | $1.8B | ||
| Q3 25 | $401.2M | $1.8B | ||
| Q2 25 | $156.3M | $1.7B | ||
| Q1 25 | $164.2M | $1.7B | ||
| Q4 24 | $228.5M | $1.7B | ||
| Q3 24 | $237.1M | $1.4B | ||
| Q2 24 | $264.3M | $1.4B |
总资产APLSELS
| Q1 26 | — | $5.7M | ||
| Q4 25 | $1.1B | $5.7B | ||
| Q3 25 | $1.1B | $5.7B | ||
| Q2 25 | $821.4M | $5.7B | ||
| Q1 25 | $807.3M | $5.6B | ||
| Q4 24 | $885.1M | $5.6B | ||
| Q3 24 | $901.9M | $5.6B | ||
| Q2 24 | $904.5M | $5.6B |
负债/权益比APLSELS
| Q1 26 | — | — | ||
| Q4 25 | — | 1.91× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSELS
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $571.1M | ||
| Q3 25 | $108.5M | $147.0M | ||
| Q2 25 | $4.4M | $131.3M | ||
| Q1 25 | $-53.4M | $193.4M | ||
| Q4 24 | $19.4M | $596.7M | ||
| Q3 24 | $34.1M | $149.5M | ||
| Q2 24 | $-8.3M | $143.1M |
自由现金流APLSELS
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $334.1M | ||
| Q3 25 | $108.3M | $75.7M | ||
| Q2 25 | $4.4M | $71.8M | ||
| Q1 25 | $-53.4M | $148.2M | ||
| Q4 24 | $19.3M | $355.4M | ||
| Q3 24 | — | $91.1M | ||
| Q2 24 | $-8.4M | $80.6M |
自由现金流率APLSELS
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 89.4% | ||
| Q3 25 | 23.6% | 19.3% | ||
| Q2 25 | 2.5% | 19.1% | ||
| Q1 25 | -32.0% | 38.3% | ||
| Q4 24 | 9.1% | 95.5% | ||
| Q3 24 | — | 23.5% | ||
| Q2 24 | -4.2% | 21.2% |
资本支出强度APLSELS
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 63.4% | ||
| Q3 25 | 0.0% | 18.1% | ||
| Q2 25 | 0.0% | 15.8% | ||
| Q1 25 | 0.0% | 11.7% | ||
| Q4 24 | 0.0% | 64.8% | ||
| Q3 24 | 0.0% | 15.1% | ||
| Q2 24 | 0.0% | 16.5% |
现金转化率APLSELS
| Q1 26 | — | — | ||
| Q4 25 | — | 5.50× | ||
| Q3 25 | 0.50× | 1.46× | ||
| Q2 25 | — | 1.57× | ||
| Q1 25 | — | 1.69× | ||
| Q4 24 | — | 5.93× | ||
| Q3 24 | — | 1.72× | ||
| Q2 24 | — | 1.74× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ELS
| Rental income | $339.0M | 85% |
| Other | $37.2M | 9% |
| Annual membership subscriptions | $18.3M | 5% |
| Membership upgrade revenue | $3.1M | 1% |
